Home/ Stocks/ XERS

Xeris Biopharma Holdings, Inc. Common Stock

XERS XNAS

$7.93 +0.59 (+7.96%) ▲ 15-min delayed

Open

$7.43

High

$8.02

Low

$7.43

Volume

2.25M

Market Cap

$1.27B

About Xeris Biopharma Holdings, Inc. Common Stock

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 435 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q4 2026	$83.13M	$2.23M	$0.01
FY 2025	$291.85M	$554.0K	$0.00
Q3 2025	$74.38M	$621.0K	$0.00
Q2 2025	$71.54M	$-1,928,000	$-0.01

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for XERS yet. Check out our latest market news or earnings calendar.

Get XERS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Xeris Biopharma Holdings, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.